Catalyst
Slingshot members are tracking this event:
Phase 2 T-Forward Data due in Early 2017 for Neurocrine's (NBIX) Ingrezza (Valbenazine) in Adults with Tourette Syndrome
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NBIX |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 17, 2017
Occurred Source:
http://phoenix.corporate-ir.net/phoenix.zhtml?c=68817&p=irol-newsArticle&ID=2237914
Related Projects
Related Keywords
Valbenazine, Vmat2 Inhibitor, Tourette Syndrome, Phase 2, T-force Green, Ingrezza
